Friday, 31 October 2014 20:50

Anticoagulation news items. Week commencing 27th October 2014

Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation


Retrospective cohort study in general practice found dabigatran linked to reduced risk of ischaemic stroke, intracranial bleed, and death, and increased risk of major GI bleed vs. warfarin in elderly patients with non-valvular AF. These links more pronounced with 150mg BD dose.


Effect of intermittent pneumatic compression on disability, living circumstances, quality of life, and hospital costs after stroke: secondary analyses from CLOTS 3, a randomised trial

The Lancet Neurology

RCT (n=2876) found despite previously reported decrease proximal DVT risk at 30 days (primary endpoint), there were no significant differences in disability, living circumstances, or health-related QoL in patients using or not using intermittent pneumatic compression.


Deep vein thrombosis, pulmonary embolism - dabigatran etexilate (treatment, prevention): final appraisal determination

National Institute for Health and Care Excellence

DRAFT guidance recommends dabigatran etexilate, within its marketing authorisation, as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults.


Common Questions and Answers on the Practical Use of Oral Anticoagulants in Non-Valvular Atrial Fibrillation

This document highlights key factors influencing anticoagulant choice, identification of patients taking anticoagulants, when might warfarin be the preferred option, and active swapping from warfarin to novel agents.


FDA advisory panel recommends approval of edoxaban 60mg in selected AF patients

Advisory panel to FDA has recommended approval of 60 mg dose of edoxaban, a once-daily anticoagulant that inhibits Factor Xa, for use in patients with AF, but only in those with mild renal impairment, as outcomes vs. warfarin were worse in those with normal renal function.


FDA Approves Obizur (Antihaemophilic Factor (Recombinant), Porcine Sequence) for Acquired Haemophilia A

US Food and Drug Administration
The US FDA has approved Obizur (Antihaemophilic Factor (Recombinant), Porcine Sequence) for the treatment of bleeding episodes in adults with acquired haemophilia A.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: